Total Payments
$595,992
2024 Payments
$127,307
Companies
109
Transactions
2,716
Medicare Patients
4,924
Medicare Billing
$506,664
Payment Breakdown by Category
Other$290,971 (48.8%)
Consulting$177,371 (29.8%)
Travel$80,709 (13.5%)
Food & Beverage$38,074 (6.4%)
Research$8,484 (1.4%)
Education$322.62 (0.1%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $289,396 | 199 | 48.6% |
| Consulting Fee | $177,371 | 87 | 29.8% |
| Travel and Lodging | $80,709 | 223 | 13.5% |
| Food and Beverage | $38,074 | 2,182 | 6.4% |
| Unspecified | $8,484 | 2 | 1.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,575 | 1 | 0.3% |
| Education | $322.62 | 21 | 0.1% |
| Gift | $59.40 | 1 | 0.0% |
Payments by Type
General
$587,508
2,714 transactions
Research
$8,484
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95,527 | 216 | $0 (2023) |
| EISAI INC. | $82,509 | 142 | $0 (2022) |
| IDORSIA PHARMACEUTICALS US INC | $53,784 | 64 | $0 (2024) |
| Amgen Inc. | $53,179 | 194 | $0 (2024) |
| Axsome Therapeutics, Inc. | $50,829 | 51 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $47,926 | 57 | $0 (2024) |
| Allergan, Inc. | $30,391 | 116 | $0 (2021) |
| ABBVIE INC. | $25,234 | 176 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $22,322 | 164 | $0 (2024) |
| Novo Nordisk Inc | $20,806 | 300 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $127,307 | 362 | Amgen Inc. ($25,505) |
| 2023 | $107,417 | 324 | IDORSIA PHARMACEUTICALS US INC ($33,988) |
| 2022 | $45,957 | 274 | EISAI INC. ($18,485) |
| 2021 | $54,445 | 308 | Eisai Inc. ($13,200) |
| 2020 | $77,683 | 375 | Eisai Inc. ($30,917) |
| 2019 | $46,019 | 352 | Eisai Inc. ($19,907) |
| 2018 | $41,896 | 322 | Merck Sharp & Dohme Corporation ($19,335) |
| 2017 | $95,268 | 399 | Merck Sharp & Dohme Corporation ($72,490) |
All Payment Transactions
2,716 individual payment records from CMS Open Payments — Page 1 of 109
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Endocrinology | ||||||
| 12/18/2024 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | Cash or cash equivalent | $30.55 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: NEUROSCIENCE | ||||||
| 12/18/2024 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| Category: Cardiology | ||||||
| 12/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Cardio-renal | ||||||
| 12/16/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 12/16/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $26.28 | General |
| Category: Neuroscience | ||||||
| 12/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $6,474.75 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $18.50 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $3.92 | General |
| Category: Inflammation | ||||||
| 12/09/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REJOYN (Device) | Consulting Fee | Cash or cash equivalent | $285.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/07/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 12/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $47.45 | General |
| Category: Obesity | ||||||
| 12/05/2024 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | Cash or cash equivalent | $36.66 | General |
| Category: Antibiotic | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $41.54 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $28.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: VACCINES | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $6.19 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $4.56 | General |
| Category: Endocrinology | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.31 | General |
| 12/02/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.73 | General |
| Category: PSYCHIATRY | ||||||
| 11/28/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,080.00 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $8,484 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,612 | 2,425 | $320,108 | $166,277 |
| 2022 | 15 | 1,073 | 1,687 | $228,618 | $120,405 |
| 2021 | 21 | 1,205 | 1,729 | $229,619 | $123,983 |
| 2020 | 22 | 1,034 | 1,532 | $192,910 | $95,999 |
Total Patients
4,924
Total Services
7,373
Medicare Billing
$506,664
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 281 | 530 | $110,240 | $48,497 | 44.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 210 | 210 | $44,520 | $28,100 | 63.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 211 | 315 | $46,398 | $20,144 | 43.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 39 | 309 | $26,574 | $15,041 | 56.6% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 33 | 33 | $12,375 | $9,292 | 75.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 107 | 107 | $9,630 | $7,690 | 79.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 23 | 26 | $11,622 | $5,887 | 50.6% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 240 | 240 | $7,440 | $4,627 | 62.2% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 26 | 26 | $6,968 | $4,445 | 63.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 114 | 114 | $3,420 | $3,352 | 98.0% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 11 | 84 | $6,972 | $3,312 | 47.5% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 14 | 14 | $3,766 | $2,399 | 63.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 17 | $4,930 | $2,367 | 48.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 11 | 49 | $4,998 | $1,975 | 39.5% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 34 | 39 | $3,510 | $1,766 | 50.3% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 11 | 11 | $3,630 | $1,741 | 48.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 36 | 36 | $1,260 | $1,154 | 91.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 40 | 61 | $2,718 | $980.70 | 36.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 12 | 18 | $1,890 | $921.77 | 48.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 14 | $1,545 | $611.26 | 39.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 16 | 22 | $1,232 | $552.30 | 44.8% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 34 | 34 | $1,360 | $409.61 | 30.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 19 | 34 | $1,540 | $399.16 | 25.9% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 24 | 39 | $780.00 | $335.06 | 43.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 21 | 21 | $504.00 | $204.85 | 40.6% |
About Dr. Paul Doghramji, MD
Dr. Paul Doghramji, MD is a Family Medicine healthcare provider based in Collegeville, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417937715.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Doghramji, MD has received a total of $595,992 in payments from pharmaceutical and medical device companies, with $127,307 received in 2024. These payments were reported across 2,716 transactions from 109 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($289,396).
As a Medicare-enrolled provider, Doghramji has provided services to 4,924 Medicare beneficiaries, totaling 7,373 services with total Medicare billing of $506,664. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Collegeville, PA
- Active Since 01/20/2006
- Last Updated 12/17/2019
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1417937715
Products in Payments
- BELSOMRA (Drug) $94,363
- Dayvigo (Drug) $62,602
- QUVIVIQ (Drug) $53,784
- Repatha (Biological) $47,483
- Sunosi (Drug) $26,744
- VRAYLAR (Drug) $26,594
- SUNOSI (Drug) $25,108
- Auvelity (Drug) $24,085
- REXULTI (Drug) $20,807
- UBRELVY (Drug) $20,781
- AIRSUPRA (Drug) $13,677
- Ozempic (Drug) $11,942
- REJOYN (Device) $11,173
- DUZALLO (Drug) $7,807
- RYBELSUS (Drug) $7,225
- Haegarda (Biological) $6,875
- ZURAMPIC (Drug) $5,468
- FASENRA (Drug) $4,999
- SPRAVATO (Drug) $4,896
- XYWAV (Drug) $4,640
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Collegeville
Birgit Wiswe, Md, MD
Family Medicine — Payments: $13,357
Family Medicine $13,357
Robert Talamo, Md, MD
Family Medicine — Payments: $5,621
Family Medicine $5,621
Timothy Fiorillo, D.o, D.O
Family Medicine — Payments: $4,957
Family Medicine $4,957
Burton Ginsberg, D.o, D.O
Family Medicine — Payments: $3,560
Family Medicine $3,560
Marta Motel, Do, DO
Family Medicine — Payments: $1,129
Family Medicine $1,129
Dr. Ching Yeung, Do, DO
Family Medicine — Payments: $1,048
Family Medicine $1,048